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Abstract 
Background: Mitral valve diseases are commonly associated with pulmonary 
hypertension. The aim of this study was to evaluate the effect of preoperative 
administration of sildenafil on the outcome after mitral valve replacement in 
patients with pulmonary hypertension. 
Methods: This prospective randomized study was carried out on 67 patients who 
had a mitral valve replacement and associated high systolic pulmonary artery 
pressure more than 50 mmHg. Patients were randomized into three groups: group 
A (n= 20) received preoperative sildenafil for one week, group B (n=22) received 
sildenafil for one month, and group C (n= 25) did not receive sildenafil. All patients 
had transthoracic echocardiography preoperatively, one week and one month 
postoperatively.  
Results: There was no difference in preoperative and operative variables among 
groups. Dobutamine support was required in 15 patients (60%) in group C vs. 6 
patients (30%) in group A and 5 patients (22.5%) in group B (p= 0.012). Duration of 
mechanical ventilation was significantly longer in group C (389.2 ± 48.79 minutes) 
compared to group A and B (295.5 ± 17.01 and 281.4 ± 39.44 minutes, respectively, 
p<0.001). ICU stay was longer in group C (61.72 ± 13.69 hours) compared to groups 
A and B (53.55 ± 14.49 and 45.64 ± 13.43 hours, respectively, p=0001). The hospital 
stay was longer in group C (8.0 ± 1.80 days) compared to group A and B (6.05 ± 0.94 
and 6.27 ± 1.24 days, respectively; p< 0.001). The transthoracic echocardiographic 
study one month after the operation showed that pulmonary artery systolic pressure 
significantly lower in groups A and B (28.30 ± 3.3 and 28.2 ± 4.98 mmHg, respectively) 
compared to group C (43.12 ± 4.99 mmHg) (p <0.001). There was no statistically 
significant difference between groups A and B regarding PASP after five days (p= 
0.287) or one month (p= 0.939). 
Conclusion: We found that preoperative administration of oral sildenafil in patients 
with pulmonary hypertension undergoing mitral valve replacement may reduce 
pulmonary hypertension postoperatively. We could not find a difference in the 
administration of sildenafil for either one week or one month preoperatively. 
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Introduction 
Mitral valve disease is commonly associated 
with pulmonary hypertension, which can lead to 
right ventricular failure and increase mortality. 
Pulmonary hypertension is defined as an increase 
of the mean pulmonary artery pressure more than 
25 mmHg at rest as assessed by right heart 
catheterization [1].  
Sildenafil is a selective pharmacological 
inhibitor of isoform 5 phosphodiesterase enzyme 
[2], which increases cyclic guanosine 
monophosphate (cGMP) levels and has shown to 
be effective for primary pulmonary hypertension 
[2, 3]. Sildenafil was also used to manage 
secondary pulmonary hypertension in the 
perioperative period in patients undergoing 
cardiac surgeries. [4]  
There are few studies on the use of sildenafil 
in the preoperative management of pulmonary 
hypertension associated with mitral valve disease 
[5]. The aim of this study was to evaluate the 
effect of preoperative administration of sildenafil 
on the outcome after mitral valve replacement in 
patients with pulmonary hypertension. 
Patients and Methods: 
Study design and patients: 
This prospective randomized study was 
conducted between March 2017 and October 
2019 at Menoufia University Hospitals. A total of 
67 patients who were scheduled for elective mitral 
valve replacement surgery with pulmonary 
hypertension (pulmonary artery systolic pressure 
≥50mmHg) were included in the study. We 
obtained written informed consent from all 
patients before the enrollment in the trial, and the 
Ethical Committee has approved the study.  
Patients were divided into three groups; group 
A (n= 20) included patients who received oral 
sildenafil 20 mg three times a day for one week 
preoperatively, group B (n= 22) included patients 
who received oral sildenafil 20 mg three times a 
day for one month preoperatively, and group C (n= 
25) included patients who did not receive
sildenafil. Patients with coronary artery disease, 
double‑valve disease, emergency cases, redo 
cases, congestive heart failure, renal or hepatic 
dysfunction, and chronic obstructive airway 
disease were excluded from the study. 
Data collection: 
Each patient was subjected to full history 
taking, thorough clinical examination, 
preoperative laboratory and radiological 
investigations, and full transthoracic 
echocardiographic assessment including 
measurement of the left ventricular end‐diastolic 
diameter (LVEDD), the left ventricular end‐systolic 
diameter (LVESD), the left atrium size, the ejection 
fraction, the mitral valve area, the Wilkins score, 
and the pulmonary artery systolic pressure. A 
transesophageal echocardiogram was done after 
induction of anesthesia and before skin incision. 
Surgical technique: 
All patients had a standard median sternotomy 
incision. After induction of anesthesia and before 
skin incision, pulmonary artery systolic pressure 
(PASP) was measured by transesophageal ECHO. 
Cardiopulmonary bypass was instituted through 
aorto-bicaval cannulation. 
Table 1: Pre-operative Data 
Variable Group A (n = 20) Group B (n = 22) Group C (n = 25) p value 
Male sex (Number (%)) 8 (40) 11 (50) 12 (48) 0.722 
Age (Mean ± SD) years 52.2 ± 8.5 51.7 ± 9.3 54.5 ± 9.3 0.526 
Systemic hypertension (Number 
(%)) 
6 (30) 8 (36.3) 9 (36) 0.611 
Diabetes Mellitus (Number (%)) 5 (25) 4 (18) 6 (24) 0.626 
Atrial fibrillation (Number (%)) 4 (20) 3 (13.6) 6 (24%) 0.683 
Dyspnea (Number (%)) 
NYHA II 11 (55.0) 11 (50) 14 (56) 
0.910 
NYHA III 9 (45.0) 11 (50) 11 (44) 
SD: standard deviation, NYHA: New York Heart Association 
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Table 2: Preoperative echocardiographic data 
Variable 
Group A 
(n = 20) 
Group B 
(n = 22) 
Group C 
(n = 25) 
p value 
EF (Mean ± SD) % 63.05 ± 6.47 64.27 ± 6.47 62.48 ± 6.90 0.647 
MVA (cm2) (Mean ± SD) 1.30 ± 0.52 1.16 ± 0.41 1.06 ± 0.28 0.481 
Wilkins score (Mean ± SD) 10.45 ± 1.10 9.77 ± 1.02 10.36 ± 1.32 0.121 
LVESD (cm) (Mean ± SD) 3.90 ± 0.62 3.64 ± 0.60 3.98 ± 0.27 0.187 
LA diameter (cm) (Mean ± SD) 4.99 ± 0.93 5.25 ± 1.14 5.10 ± 0.89 0.638 




Mitral stenosis  11 (55) 10 (45.5) 12 (48) 
0.927 Mitral regurgitation 6 (30) 6 (27.3) 7 (28) 
Double mitral 3 (15) 6 (27.3) 6 (24) 
Mitral etiology 
(Number (%)) 
Rheumatic 18 (9) 19 (86.4) 21 (84) 
0.906 
Degenerative 2 (20) 3 (13.6) 4 (16) 
PASP (Mean ± SD) mmHg 61.25 ± 6.46 61.86 ± 7.25 62.20 ± 6.25 0.289 
SD: standard deviation, EF: ejection fraction, MVA: mitral valve area, LVESD: left ventricular end-systolic 
diameter, LA: left atrial, LVEDD: left ventricular end-diastolic diameter, PASP: pulmonary artery systolic 
pressure 
Aorta was cross-clamped and cardiac arrest 
induced by infusion of cold potassium cardioplegic 
solution into the aortic root. The left atrium was 
approached though the interatrial groove. We 
used mechanical valves in all cases for the 
replacement of the mitral valve [6,7]. 
Twenty minutes post cardiopulmonary bypass, 
PASP was measured by transesophageal ECHO. 
Inotropes were titrated and recorded according to 
patient hemodynamics.   
Patients were transferred intubated to the ICU 
with care focused on control of patients’ 
hemodynamics. Transthoracic echocardiogram 
was performed before discharge on postoperative 
day 5-7 and was repeated in the outpatient clinic 
one month after the surgery. 
Statistical analysis: 
All preoperative, operative, postoperative, 
and outpatient follow‐up data were collected. 
Quantitative variables were expressed as mean ± 
standard deviation, whereas qualitative data were 
expressed as number (n) and percentage. 
Statistical significance was tested using IBM SPSS 
statistics software package (version 19; SPSS Inc., 
Chicago, Illinois, USA). The significance of 
quantitative variables was tested using analysis of 
variance test (ANOVA), while Chi-square or Fisher 
exact test was used for qualitative data. We 
considered probability values less than 0.05 as 
statistically significant. 
Results 
We noticed no statistically significant 
difference between the three groups regarding; 
demographic data, patients’ preoperative 
comorbidities, preoperative NYHA class, or 
preoperative echocardiographic data (Table 1 and 
Table 2). 
PASP post cardiopulmonary bypass was 
statistically significantly lower in groups A and B 
than in group C (p <0.001) (Table 3).
Table 3: Intra-operative transesophageal echocardiographic data post cardiopulmonary bypass weaning 
Variable Group A (n = 20) Group B (n = 22) Group C (n = 25) p value 
EF (Mean ± SD) % 62.25 ± 6.97 63.23 ± 6.84 63.12 ± 6.90 0.882 
PASP (Mean ± SD) mmHg  35.60 ± 4.12 32.00 ± 5.35 50.0 ± 6.01 <0.001 
SD: standard deviation, EF: ejection fraction, PASP: pulmonary artery systolic pressure 
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Table 4: Operative data 
Intraoperative data 
Group A (n = 20) 
(Mean ± SD) 
Group B (n = 22) 
(Mean ± SD) 
Group C (n = 25) 
(Mean ± SD) 
p-value 
Aortic cross clamp time (minutes) 44.45 ± 3.86 41.95 ± 3.72 45.40 ± 13.67 0.227 
Total bypass time (minutes) 63.05 ± 3.15 62.09 ± 3.05 67.52 ± 17.82 0.559 
Total operative time (minutes) 108.4 ± 14.04 107.5 ± 7.52 109.1 ± 11.09 0.794 
SD: standard deviation 
 Mean pulmonary artery systolic pressure was 
reduced in group A from 61.25 ± 6.46 mmHg 
preoperatively to 35.60 ± 4.12 mmHg post 
cardiopulmonary bypass (CPB) weaning and in 
group B from 61.86 ± 7.25 mmHg preoperatively 
to 32.00 ± 5.35 mmHg post CPB weaning (Table 2 
and Table 3). 
Regarding operative data, there was no 
statistically significant difference between the 
three groups regarding; the aortic cross-clamp 
time (p= 0.227), the total cardiopulmonary bypass 
time (p = 0.559), or the total operative time (p= 
0.794) (Table 4). The duration of mechanical 
ventilation, intensive care unit (ICU) stay, and total 
hospital stay were all statistically significantly 
higher in group C than both groups A and B; 
however, there was no statistically significant 
difference between groups A and B regarding 
these durations (p= 0.137, 0.075 and 0.519, 
respectively) (Table 5). Postoperative 
complications and postoperative mortality 
showed no statistically significant difference 
between the three groups (Table 5). 
There was no statistically significant difference 
between the three groups regarding the number 
of patients who received norepinephrine, dose, 
or duration of treatment (Table 6). However, the 
number of patients needed treatment with 
dobutamine was higher in group C than both 
groups A and B, and the difference was statistically 
significant, although there was no statistically 
significant difference between the treated 
patients in the three groups regarding the dose 
or duration of treatment (Table 6). The number 
of cases needed postoperative treatment with 
glyceryl trinitrate, and milrinone was statistically 
significantly higher in group C than both groups A 
and B (p <0.001 and 0.019, respectively) (Table 6). 
The transthoracic echocardiographic study 5 
days and one month after the operation showed 
that pulmonary artery systolic pressure (PASP) 
was significantly lower in groups A and B than in 
group C and this difference was highly statistically 
significant (p-value <0.001) (Table 7 and Table 8). 
However, there was no statistically significant 
difference between groups A and B regarding 
PASP after five days (p= 0.287) or one month (p= 
0.939) (Table 7 and Table 8). There was no 
statistically significant difference between the 
three groups regarding; ejection fraction (EF), 
mitral valve (MV) pressure gradient, left 
ventricular end-systolic diameter (LVESD), left 
atrial (LA) diameter or left ventricular end-
diastolic diameter (LVEDD); either in 5-7 days or 
one-month postoperative echocardiographic 
study (Table 7 and Table 8).
Table 5: Postoperative data 
Variables Group A (n = 20) Group B (n = 22) Group C (n = 25) p value 
Ventilation time (minutes) (Mean ± SD) 295.5 ± 17.01 281.4 ± 39.44 389.2 ± 48.79 <0.001 
ICU stay (hours) (Mean ± SD) 53.55 ± 14.49 45.64 ± 13.43 61.72 ± 13.69 0.001 
Hospital stay (days) (Mean ± SD) 6.05 ± 0.94 6.27 ± 1.24 8.0 ± 1.80 <0.001 
Re-exploration (Number (%)) 1 (5%) 1 (4.5%) 1 (4%) ˃0.99 
Sternal wound infection (Number (%)) 2 (10%). 2 (9.1%) 3 (12%) 0.899 
New atrial fibrillation (Number (%)) 8 (40%) 6 (27.2 %) 8 (32%) 0.785 
Mortality (Number (%)) 0 0 1 (4%) 0.921 
SD: standard deviation, ICU: intensive care unit 
The Egyptian Cardiothoracic Surgeon 
152 
Table 6: postoperative inotropic support and vasodilators use 
Postoperative drugs 
Group A 
(n = 20) 
Group B 
(n = 22) 
Group C 




Number (%) 2 (10.0) 2 (9.1) 6 (24) 0.362 
Duration (Mean ± SD) hours 5.0 ± 1.41 5.0 ± 0.0 5.67 ± 0.61 0.385 
Dose (Mean ± SD) mg/ml 0.07 ± 0.02 0.05 ± 0.01 0.07 ± 0.02 0.310 
Dobutamine 
Number (%) 6 (30) 5 (22.5) 15 (60) 0.012 
Duration (Mean ± SD) hours 5.60 ± 0.89 5.10 ± 0.89 5.43 ± 0.90 0.691 
Dose (Mean ± SD) mg/ml 7.40 ± 1.82 5.40 ± 1.52 7.07 ± 2.15 0.161 
Glyceryl Trinitrate (Number (%)) 3 (15) 4 (18.2) 16 (64) <0.001 
Milrinone (Number (%)) 3 (15) 2 (9.1) 11 (44) 0.019 
SD: standard deviation 
Concerning mortality, 1 (5%) patient in Group 
C had passed away intraoperatively because of 
vasoplegia as a result of hypersensitivity from 
transfusion of fresh frozen plasma. There was no 
significant statistical difference between the three 
groups (p= 0.921). 
Discussion 
We performed this study to evaluate the effect 
of preoperative administration of sildenafil on 
operative and early postoperative outcome after 
mitral valve replacement in patients with 
pulmonary hypertension. Pulmonary 
hypertension affects almost all patients with 
severe symptomatic mitral valve disease [8]. 
Mitral valve diseases increase left atrial pressure, 
which leads to an initially passive and potentially 
reversible increase in pulmonary artery pressure. 
Vascular injury then triggers a cascade of venous 
and small artery remodeling, which result in non-
reversible arterial pulmonary hypertension, and 
eventually, right ventricular dysfunction [9]. In 
our study, the mean age in group A was 52.2 ± 
8.5 years, in group B was 51.7 ± 9.3 years, and in 
group C was 54.5 ± 9.3 years. There was no 
statistically significant difference between the 
three groups regarding age (p= 0.526). There was 
no statistically significant difference between the 
three groups regarding the preoperative 
echocardiographic data. 
We performed intraoperative transesophageal 
echocardiography immediately post 
cardiopulmonary bypass (CPB) weaning for all 
patients included in our study. The mean PASP for 
group A was 35.60 ± 4.12 mmHg, for group B was 
32.00 ± 5.35 mmHg and was 50.0 ± 6.01 mmHg in 
group C. The difference was statistically significant 
between group C and the two other groups (p 
<0.001). However, there was no statistically 
significant difference between group A and B 
regarding PASP. 
Table 7: Echocardiographic data 5-7 days postoperative 
Variable 
Group A 
(n = 20) 
Group B 
(n = 22) 
Group C 
(n = 25) 
p value 
EF (Mean ± SD) % 62.25 ± 6.97 63.23 ± 6.84 63.12 ± 6.90 0.882 
MV pressure gradient (Mean ± SD) 
mmHg 
4.60 ± 0.50 4.59 ± 0.50 4.56 ± 0.51 0.960 
LVESD (cm) (Mean ± SD) 3.88 ± 0.62 3.64 ± 0.60 3.88 ± 0.37 0.189 
LA diameter (cm) (Mean ± SD) 4.89 ± 0.91 5.16 ± 1.08 5.05 ± 0.86 0.638 
LVEDD (cm) (Mean ± SD) 5.2 ± 0.2 5.0 ±.2 5.12 ±.3 0.860 
PASP (Mean ± SD) mmHg 31.04 ± 3.9 29.69 ± 4.2 46.4 ± 5.6 <0.001 
SD: standard deviation, EF: ejection fraction, MV: mitral valve, LVESD: left ventricular end-systolic 




Table 8: Echocardiographic data one month postoperative 
Variable 
Group A 
(n = 20) 
Group B 
(n = 22) 
Group C 
(n = 25) 
p value 
EF (Mean ± SD) 61.90 ± 5.96 61.95 ± 5.74 61.60 ± 6.36 0.977 
MV pressure gradient (Mean ± SD) mmHg 4.60 ± 0.50 4.59 ± 0.50 4.56 ± 0.51 0.960 
LVESD (cm) (Mean ± SD) 3.99 ± 0.52 3.54 ± 0.60 3.98 ± 0.37 0.199 
LA diameter (cm) (Mean ± SD) 4.9 ± 0.91 5.26 ± 1.08 5.15 ± 0.86 0.648 
LVEDD (cm) (Mean ± SD) 5.26 ± 0.30 5.1±.31 5.0± 0.34 0.972 
PASP (Mean ± SD) mmHg 28.30 ± 3.3 28.2 ± 4.98 43.12 ± 4.99 <0.001 
SD: standard deviation, EF: ejection fraction, MV: mitral valve, LVESD: left ventricular end-systolic 
diameter, LA: left atrial, LVEDD: left ventricular end-diastolic diameter, PASP: pulmonary artery systolic 
pressure 
Our results agree with the results of Gandhi 
and colleagues [10] who studied 40 patients 
scheduled for a mitral valve replacement with 
severe pulmonary hypertension and were 
randomly treated with oral sildenafil 25 mg (n = 
20) or placebo (n = 20) for 24 hours before surgery.
They found that systolic and mean pulmonary 
artery pressures were significantly lower (p < 
0.0001) in the sildenafil group than the placebo 
group at all times.  
In our study, we demonstrated that 
preoperative sildenafil administration significantly 
decreased the pulmonary artery systolic pressure 
(PASP) during the perioperative period, and this 
decrease in PASP continued to the postoperative 
period up to one month after surgery for patients 
who received sildenafil. This reduction could be 
explained by the relaxant effect of sildenafil on the 
pulmonary arterial wall.  
Regarding operative data, there was no 
statistically significant difference between the 
three groups regarding the bypass time, the aortic 
cross-clamp time, and the total operative 
duration. The postoperative recovery was 
significantly shorter in the two groups who 
received sildenafil than the control group (group 
C), with shorter mechanical ventilation time (p < 
0.001), ICU stay (p = 0.001), and hospital stay (p < 
0.001). Gandhi and associates [10] found that 
postoperative parameters like ventilation time 
and postoperative ICU stay time were significantly 
lower in the sildenafil group (p= 0.011) as 
compared with the control group [10]. 
In our study, the number of patients who 
needed treatment with dobutamine, glyceryl 
trinitrate, and milrinone was statistically 
significantly higher in group C than both groups A 
and B. However; there was no statistically 
significant difference between the three groups 
regarding the number of patients who received 
norepinephrine. This was similar to the results 
found by Gandhi and coworkers [10]. Shim and 
associates found that the numbers of patients 
requiring norepinephrine and milrinone were 
similar between the groups [4]. 
The transthoracic echocardiographic study five 
days and one month after the operation showed 
that pulmonary artery systolic pressure (PASP) 
was statistically significantly lower in groups A and 
B than in group C. However, there was no 
statistically significant difference between groups 
A and B regarding PASP in either 
echocardiographic data.  
There are few studies about the effect of 
sildenafil on postoperative PASP with no 
echocardiographic studies were done beyond the 
early postoperative period.  
As there was no statistically significant 
difference between the echocardiographic 
findings, operative or postoperative outcome for 
patients who received sildenafil for one week 
preoperatively (group A) and patient who received 
sildenafil for one month preoperatively (group B); 
giving sildenafil for those patients for more than 
one week preoperatively is not needed. 
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We had only one case of mortality in group C 
who died intraoperatively most likely due to 
severe reaction to fresh frozen plasma 
transfusion. However, there was no statistically 
significant difference between the three groups 
regarding postoperative complications and 
postoperative mortality. 
Study limitations 
The study is limited by the number of patients, 
and it is a single-center experience, and 
generalization of the results may not be possible. 
Conclusion 
We found that the preoperative 
administration of oral sildenafil in patients 
undergoing mitral valve replacement with 
pulmonary hypertension may reduce pulmonary 
hypertension postoperatively. We could not find a 
difference in the administration of sildenafil for 
either one week or one month preoperatively. 
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